YLR159C-A Antibody

What is YLR159C-A and why is it studied?

YLR159C-A is a gene that encodes a putative protein of unknown function identified through fungal homology comparisons and RT-PCR. It is part of the S. cerevisiae reference genome (strain S288C) but lacks phenotypic, regulatory, or functional annotations in the Saccharomyces Genome Database (SGD). Currently, no biological processes, molecular functions, or cellular components are associated with this protein. The scientific interest primarily stems from fundamental research into fungal proteomics and the potential discovery of novel functional proteins in yeast that may have evolutionary significance.

What are the specifications of commercially available YLR159C-A antibodies?

The YLR159C-A antibody available for research is primarily a polyclonal antibody produced for detecting the uncharacterized protein YLR159C-A. Key specifications include:

This antibody is designed for experimental detection of the YLR159C-A protein, though peer-reviewed validation studies remain absent from the literature.

How does YLR159C-A antibody validation compare to standard antibody validation practices?

Unlike well-characterized antibodies, the YLR159C-A antibody lacks comprehensive validation according to current research standards. Modern antibody validation typically requires multiple approaches including: (1) genetic knockouts as negative controls, (2) orthogonal validation using alternative detection methods, (3) independent antibody validation using antibodies targeting different epitopes, (4) expression modulation experiments, and (5) immunocapture followed by mass spectrometry. For YLR159C-A antibody, peer-reviewed validation studies have not been published, highlighting a significant gap in its characterization compared to antibodies for more extensively studied proteins .

What control experiments are essential when using YLR159C-A antibody?

When working with poorly characterized antibodies like YLR159C-A, rigorous controls are crucial. Based on contemporary antibody validation practices, researchers should implement:

• Negative controls: Ideally, use S. cerevisiae strains with YLR159C-A knocked out. Recent studies have demonstrated that knockout cell lines provide superior control compared to other approaches, particularly for Western blots and immunofluorescence .

• Positive controls: Express recombinant YLR159C-A protein in a heterologous system where the protein is normally absent.

• Epitope competition assays: Pre-incubate the antibody with purified YLR159C-A peptide/protein to demonstrate binding specificity.

• Secondary antibody-only controls: To distinguish between specific binding and background signal.

• Cross-reactivity assessment: Test the antibody against closely related proteins or in organisms without YLR159C-A homologs .

What methods can be used to determine the specificity of YLR159C-A antibody?

To determine the specificity of YLR159C-A antibody, researchers should employ multiple complementary approaches:

• Western blot analysis: Using wild-type and YLR159C-A knockout yeast strains to confirm detection of a single band at the expected molecular weight only in wild-type samples.

• Immunoprecipitation followed by mass spectrometry: To identify all proteins captured by the antibody and confirm YLR159C-A as the primary target.

• Immunofluorescence with knockout controls: To verify subcellular localization patterns and absence of signal in knockout strains.

• Heterologous expression systems: Expressing tagged YLR159C-A in systems like E. coli or mammalian cells and confirming co-localization of antibody signal with the tag.

• Sequential epitope mapping: To identify the specific binding region and assess potential cross-reactivity with related sequences .

How should YLR159C-A antibody be validated for different experimental applications?

Validation must be application-specific since antibodies that work in one application may fail in others. For YLR159C-A:

• For Western blotting: Validate by comparing signals between wild-type and knockout strains, assessing single-band specificity, and comparing results with recombinant protein standards.

• For immunoprecipitation: Validate by mass spectrometry identification of pulled-down proteins, confirming enrichment of YLR159C-A.

• For immunofluorescence: Compare staining patterns in wild-type and knockout strains, perform co-localization with tagged constructs, and test antibody dilutions to optimize signal-to-noise ratio.

• For ELISA applications: Establish standard curves with recombinant protein, determine limits of detection, and test for cross-reactivity with related proteins.

• For ChIP applications: If relevant, validate by comparing with tagged YLR159C-A constructs and appropriate negative controls .

How should researchers interpret Western blot results with YLR159C-A antibody?

When interpreting Western blot results using YLR159C-A antibody, researchers should consider:

• Band specificity: A specific band should appear at the expected molecular weight (~12 kDa for YLR159C-A) only in wild-type samples and be absent in knockout controls.

• Signal intensity: The intensity should correlate with known or manipulated expression levels of YLR159C-A.

• Additional bands: Any bands beyond the expected size require thorough investigation to determine if they represent post-translational modifications, degradation products, or non-specific binding.

• Reproducibility: Results should be reproducible across multiple experiments and protein preparations.

• Loading controls: Always include appropriate loading controls to normalize signal intensity and confirm equal protein loading.

Researchers should approach results cautiously, as a recent study demonstrated that an average of ~12 publications per protein target included data from antibodies that failed to recognize the relevant target protein .

What potential confounding factors might affect YLR159C-A antibody performance?

Several factors may confound experimental results with YLR159C-A antibody:

• Batch variability: Polyclonal antibodies like YLR159C-A antibody may show lot-to-lot variation affecting specificity and sensitivity.

• Post-translational modifications: If YLR159C-A undergoes phosphorylation, glycosylation, or other modifications, antibody binding may be affected.

• Protein conformation: Native versus denatured conditions may significantly affect epitope accessibility.

• Sample preparation methods: Different lysis buffers, fixation techniques, or heating conditions may alter protein structure and antibody binding.

• Expression levels: Very low endogenous expression of YLR159C-A may require signal amplification techniques, increasing the risk of non-specific background.

• Cross-reactivity with related proteins: The antibody may detect proteins with similar epitopes, especially problematic since YLR159C-A's function and related proteins remain poorly characterized .

How do YLR159C-A antibody results compare with orthogonal detection methods?

• RNA-seq or RT-qPCR: To correlate protein detection with mRNA expression levels.

• Mass spectrometry: For label-free protein identification and quantification.

• Epitope tagging: Introducing FLAG, HA, or GFP tags to YLR159C-A for detection with well-characterized tag-specific antibodies.

• CRISPR-Cas9 editing: Creating endogenously tagged versions for correlation with antibody results.

Recent antibody characterization studies demonstrate that concordance between orthogonal methods significantly increases confidence in antibody specificity .

How might YLR159C-A antibody be utilized in protein localization studies?

For subcellular localization studies of YLR159C-A in S. cerevisiae, researchers should:

• Optimize immunofluorescence protocols: Determine optimal fixation methods, permeabilization conditions, and antibody concentrations.

• Employ co-localization markers: Use established organelle markers to identify compartmentalization patterns.

• Compare with tagged constructs: Correlate antibody-based localization with fluorescent protein-tagged YLR159C-A.

• Implement super-resolution microscopy: For detailed localization beyond the diffraction limit.

• Perform fractionation studies: Combine with Western blotting of cellular fractions to biochemically validate localization patterns.

• Analyze localization changes: Investigate potential relocalization under different growth conditions or cellular stresses.

What approaches can identify potential YLR159C-A protein interaction partners?

To identify interaction partners of this uncharacterized protein, researchers could employ:

• Immunoprecipitation-mass spectrometry (IP-MS): Using YLR159C-A antibody to pull down the protein and its interactors, followed by MS identification.

• Proximity labeling approaches: Expressing YLR159C-A fused to BioID or APEX2 to identify proximal proteins.

• Yeast two-hybrid screening: To identify direct protein-protein interactions.

• Co-immunoprecipitation with suspected partners: Based on predictions from homology or functional genomics data.

• Cross-linking mass spectrometry: To capture transient interactions.

For all approaches, appropriate controls must be included to distinguish specific from non-specific interactions, particularly important given the potential limitations in YLR159C-A antibody specificity.

How can expression analysis of YLR159C-A be conducted under different conditions?

To analyze YLR159C-A expression under varying growth conditions, researchers should:

• Establish baseline expression: Determine normal expression levels in standard growth conditions using both antibody-based methods and transcript analysis.

• Test various stress conditions: Examine expression changes under nutrient limitation, temperature stress, osmotic stress, and oxidative stress.

• Investigate cell cycle dependence: Synchronize cells and analyze expression throughout cell cycle progression.

• Assess strain variations: Compare expression across different S. cerevisiae strains.

• Quantitative analysis: Use quantitative Western blotting with appropriate standards and statistical analysis of biological replicates.

• Correlation analysis: Compare protein expression data with transcriptomic data to identify post-transcriptional regulation.

What steps should be taken if YLR159C-A antibody shows inconsistent results?

When facing inconsistent results with YLR159C-A antibody, researchers should:

• Review antibody handling: Ensure proper storage, avoid freeze-thaw cycles, and check for precipitates.

• Optimize experimental conditions: Systematically vary antibody concentration, incubation time/temperature, washing stringency, and blocking reagents.

• Test multiple lots: If available, compare performance across different antibody lots.

• Validate specificity: Implement knockout controls or epitope competition assays to confirm specificity.

• Compare with tagged constructs: Use epitope-tagged YLR159C-A as an alternative detection method.

• Consider protein abundance: Low abundance may require signal amplification or enrichment strategies.

• Consult literature: Though limited for YLR159C-A specifically, review general troubleshooting approaches for similar antibodies in yeast studies .

How can researchers contribute to improving YLR159C-A antibody characterization?

To advance YLR159C-A antibody characterization, researchers should:

• Implement rigorous validation: Apply the five pillars of antibody validation: genetic, orthogonal, independent antibody, expression modulation, and immunocapture-MS.

• Share validation data: Publish validation results, even negative findings, to build collective knowledge.

• Deposit detailed protocols: Document exact conditions for successful experiments in repositories like protocols.io.

• Report lot information: Always include antibody catalog numbers, lot numbers, and dilutions in publications.

• Generate knockout controls: Develop and share YLR159C-A knockout strains as community resources.

• Collaborate with validation initiatives: Engage with groups like YCharOS that systematically characterize antibodies.

• Develop alternative detection methods: Create complementary approaches that don't rely solely on antibodies .

What are the latest advancements in antibody validation technology relevant to YLR159C-A research?

Recent advancements in antibody validation technology that could benefit YLR159C-A research include:

• CRISPR-Cas9 knockout cell lines: Streamlined generation of knockout controls specific for antibody validation.

• Automated Western blot systems: Improved reproducibility and quantification for antibody validation.

• Single-cell proteomics: Enabling correlation between antibody-based detection and single-cell protein quantification.

• Recombinant antibody technology: Recent studies show recombinant antibodies outperform both monoclonal and polyclonal antibodies across multiple assays.

• Antibody validation databases: Growing resources that compile validation data across multiple targets and applications.

• Standardized validation protocols: Community-developed standards for minimum validation requirements.

The YCharOS group recently published findings showing that 50-75% of proteins were covered by at least one high-performing commercial antibody depending on the application, suggesting potential for development of better characterized YLR159C-A antibodies in the future .

What is the current research status of YLR159C-A antibody and what future developments are needed?

The current research status of YLR159C-A antibody is preliminary, with significant gaps in characterization and validation. As of 2025, no peer-reviewed studies have specifically investigated this antibody or its target protein. The target remains functionally uncharacterized, and the antibody lacks published validation for specificity, sensitivity, or cross-reactivity.

Future developments needed include:

• Comprehensive validation studies: Applying rigorous validation methodologies to current YLR159C-A antibodies.

• Functional characterization of the target: Determining the biological role of YLR159C-A protein.

• Development of recombinant antibodies: Creating renewable, consistent alternatives to polyclonal antibodies.

• Application-specific protocols: Establishing optimized conditions for various experimental applications.

• Integration with -omics data: Correlating antibody-based detection with transcriptomic and proteomic profiles.

Progress in these areas would significantly enhance the reliability and utility of YLR159C-A antibody as a research tool .